Adrenal cortical carcinoma (ACC) is a rare malignancy with an incidence of one to two per one million individuals per year but represents ∼13% of adrenal tumors \>4 cm in referral endocrine centers \[[@B1]\]. ACC occurs most frequently in the fifth to sixth decade of life and demonstrates a female-to-male predominance of 2.5 to 1. Although most ACCs are sporadic, these can also occur as part of an hereditary syndrome, such as Li-Fraumeni syndrome, multiple endocrine neoplasia type 1, Beckwith--Wiedemann syndrome, familial adenopolymatosis, neurofibromatosis type 1, Carney complex, and Lynch syndrome (LS) \[[@B2]\]. Despite the large tumor size on presentation, approximately one-half of patients with ACC is discovered incidentally (42%), with a smaller proportion of patients presenting with hormonal excess (31%) or with symptoms of mass effect (20%) or discovered during cancer-staging imaging for another malignancy (6%) and during evaluation of B symptoms (1%) \[[@B3]\]. Early discovery is key to assure a better prognosis.

LS-hereditary nonpolyposis colorectal cancer is an autosomal-dominant hereditary cancer predisposition syndrome caused by germline pathogenic variants in any of DNA mismatch repair genes \[[@B4]\], including MLH1, MSH2, MSH6, and PMS2 \[[@B5]\]. Patients with LS demonstrate a substantial lifetime risk of developing colorectal (80%) and endometrial cancer (60%) \[[@B4], [@B6]\]. Germline pathogenic variants in the MSH6 gene account for ∼18% of LS cases \[[@B7]\]. Association of ACC with LS has been reported only in several case reports and one small prospective study, totaling 12 patients ([Table 1](#tbl1){ref-type="table"}) \[[@B5], [@B8]\].

###### 

Previous Reports of Patients With LS and ACC

  Studies      Age   Sex    MSH Type   Microsatellite Stability   Mode of Discovery                                                                                    Tumor Size, mm      Adrenal Hormone Excess                     Treatment   Mitotic Count   Outcome                    Criteria
  ------------ ----- ------ ---------- -------------------------- ---------------------------------------------------------------------------------------------------- ------------------- ------------------------------------------ ----------- --------------- -------------------------- --------------------------------
  \[[@B8]\]    44    M      NR         NR                         NR                                                                                                   NR                  NR                                         NR          NR              Died of disease            NR
  \[[@B9]\]    65    F      MSH2       MSS                        Cushingoid features                                                                                  NR                  ACTH-independent Cushing                   S           130/50 HPF      Died of disease            Didn't meet Amsterdam criteria
  \[[@B10]\]   34    M      MSH2       MSS                        Symptoms of hypertension and hypokalemia (possible primary hyperaldosteronism) leading to imaging)   40                  NR (possible primary hyperaldosteronism)   S           NR              Died of disease            Met Amsterdam criteria II
  \[[@B11]\]   60    F      MSH2       MSS                        Follow-up MRI for breast cancer                                                                      51                  NR                                         S           NR              Alive                      Met Amsterdam criteria
  \[[@B5]\]    29    M      MSH2       MSS                        Flank pain                                                                                           NR                  NR                                         S           20/50 HPF       Alive                      NR
  \[[@B12]\]   52    M      MSH2       MSS                        Genetic evaluation                                                                                   NR                  NR                                         NR          NR              Alive                      Met Amsterdam criteria I
  47           M     MLH1   MSS        Genetic evaluation         NR                                                                                                   NR                  NR                                         NR          Alive           Met Amsterdam criteria I   
  39           M     MSH6   MSS        Genetic evaluation         NR                                                                                                   NR                  NR                                         NR          Alive           NR                         
  42           F     MSH2   MSS        Genetic evaluation         NR                                                                                                   NR                  NR                                         NR          Alive           NR                         
  23           F     MSH2   NR         Genetic evaluation         NR                                                                                                   NR                  NR                                         NR          Alive           NR                         
  \[[@B13]\]   54    F      MSH2       NR                         Lion pain, weight loss, and lethargy                                                                 140                 None                                       S           1/50 HPF        Alive                      Met Amsterdam criteria II
  \[[@B14]\]   68    M      MSH2       NR                         Abdominal pain                                                                                       41(Extra adrenal)                                              S           2/10 HPF        Alive                      Met Amsterdam criteria II
  This study   65    F      MSH6       NR                         Incidental discovery                                                                                 92                  Androgen, estrogen excess                  S           40/50 HPF       Alive                      NR

Abbreviations: ACTH, adrenocorticotropic hormone; F, female; HPF, high-power field; M, male; MSS, microsatellite stable; NR, not reported; S, surgical.

1. Case Report {#s5}
==============

A 65-year-old woman with a past medical history of hypertension presented for evaluation of a recently developed vaginal bleeding. Transvaginal ultrasound demonstrated endometrial thickening and two uterine fibroids. The patient was treated with dilation and curettage of endometrial hyperplasia, and pathology was benign. Incidentally, on the same initial ultrasound, a large heterogeneous mass within the right upper quadrant of the abdomen was also noted. To investigate this finding further, an abdominal CT scan was performed and revealed a heterogeneous right adrenal mass, 6.0 × 5.1 × 7.8 cm ([Fig. 1A](#fig1){ref-type="fig"}). The patient was referred to the Mayo Clinic for further evaluation of the right adrenal mass.

![(a, left) Axial CT image and (right) coronal CT image showing a 6.0 × 5.1 × 7.8-cm right adrenal mass (arrows). (b) Gross pathology serial cut sections of a 9.2-cm right ACC.](js.2019-00050f1){#fig1}

Notably, as a result of a recent diagnosis of LS in the patient's sister, our patient was tested positive for familial pathogenic variant in MSH6. A recent colonoscopy was normal.

A. Investigations {#s6}
-----------------

During evaluation in the adrenal clinic, the patient was mostly asymptomatic, although she did complain of some fatigue, loss of appetite, and a 3-pound weight loss over the prior 2 weeks (which she thought was a result of anxiety related to the recent diagnosis of the adrenal mass). On physical examination, she did not have Cushingoid features, acne, or hirsutism. Her blood pressure was 135/83 mmHg, and no clinical features suggestive of primary hyperaldosteronism, such edema or hypokalemia, were present. Biochemical work-up was negative for pheochromocytoma but demonstrated evidence of androgen excess, elevated serum steroid precursors, and estrogen excess, which could have explained the patient's recent uterine bleeding ([Table 2](#tbl2){ref-type="table"}). In addition, the patient demonstrated evidence of adrenocorticotropic hormone (ACTH) independent cortisol excess based on abnormal cortisol concentrations after 1 mg overnight dexamethasone administration, along with low ACTH and elevated 24-hour, urine-free cortisol ([Table 2](#tbl2){ref-type="table"}). Urine multisteroid profiling was performed and was highly suspicious for ACC ([Table 2](#tbl2){ref-type="table"}). Based on the clinical, biochemical, and imaging presentation, ACC was suspected, and adrenalectomy was recommended.

###### 

Results of Biochemical Testing Demonstrate Androgen-, Estrogen-, and Corticotrophin-Independent Cortisol Excess

  --------------------------------------------------------------------------------------------------------------------
  Laboratory Test                                        Before Surgery   1 Mo After Surgery   Reference Range
  ------------------------------------------------------ ---------------- -------------------- -----------------------
  24-h Urine                                                                                   

  Urine-free cortisol, μg/24 h                           68               N/A                  3.5--45

  Serum                                                                                        

  ACTH, pg/mL                                            \<5              N/A                  7.2--63

  8 [am]{.smallcaps} Serum cortisol following\           13               N/A                  \<1.8
  1 mg overnight dexamethasone suppression test, μg/dL                                         

  Aldosterone, ng/dL                                     20               N/A                  ≤21

  Renin plasma activity, ng/mL/h                         2                N/A                  0.6--3.0

  Androstenedione, ng/dL                                 151              N/A                  30--200

  DHEA sulfate, μg/dL                                    403              \<15                 \<15--157

  17-Hydroxyprogesterone, ng/dL                          167              \<40                 \<51

  17-Hydroxypregnenolone, ng/dL                          888              \<16                 31--455

  Total testosterone, ng/dL                              30               \<7                  8--60

  Estradiol, pg/mL                                       113              \<10                 \<10 (Postmenopausal)
  --------------------------------------------------------------------------------------------------------------------

Abbreviations: DHEA, dehydroepiandrosterone; N/A, not available.

B. Treatment {#s7}
------------

Patient was treated with an open right adrenalectomy. Final pathology demonstrated a 9.2 × 5.9 × 4.8-cm adrenal oncocytic ACC ([Fig. 1B](#fig1){ref-type="fig"}) with focal extracapsular extension into periadrenal adipose tissue, a Ki-67 index of 15%, and a peak mitotic count of 40 mitoses in 50 high-powered fields. Surgical margins were negative for tumor. Postoperatively, the patient was treated with glucocorticoid-replacement therapy, and treatment with mitotane was started 6 weeks after surgery.

C. Outcome and Follow-Up {#s8}
------------------------

During the subsequent 26-months of follow-up, the patient remains in remission: imaging demonstrates no evidence for local recurrence or metastatic disease. In addition, patient's serum and urinary steroid biomarkers are within normal ranges.

2. Discussion {#s9}
=============

We present a rare case of a patient with LS whose only presentation was incidentally discovered ACC. Outside from ACC, she had no other manifestations of LS at the time of this case report.

Only 13 cases (including our case) have been reported so far in the literature ([Table 1](#tbl1){ref-type="table"}). The median age of presentation was 47 years (range: 23 to 68), and 46% were women. The first association of ACC with LS was described in the "N family" of two large Midwestern kindreds by H. T. Lynch in 1966 \[[@B8]\]. Proband from the N family died at age 44 from ACC, whereas his siblings presented with multiple primary colon carcinomas, endometrium carcinomas, and other cancers \[[@B8]\]. Later, three other case reports demonstrated an association of ACC with LS in patients with the *MSH2* germline mutation \[[@B5], [@B10], [@B11]\]. In 2013, a prospective study of 114 patients with ACC demonstrated a 3.2% prevalence of LS, which is higher than in the general population (0.2%) and comparable to the prevalence of LS in patients with colorectal cancer and endometrial cancer (1% to 5%) \[[@B12]\]. In this study, five of 114 patients with ACC and LS had *MSH2* (in three patients), *MSH6* (one patient), and *MLH1* (one patient) germline mutations, with four patients demonstrating microsatellite stability. More recently, two more case reports published in 2016 and 2018 \[[@B13], [@B14]\] again showed association between LS and ACC with *MSH2* germline mutation.

It is challenging to diagnose ACC early in an asymptomatic phase, before substantial growth and metastases occur. The diagnosis of ACC is based on clinical presentation and imaging characteristics of adrenal mass (Hounsfield units \>10, size \>4 cm, and heterogeneous). In patients with a genetic predisposition of ACC (such as Li-Fraumeni syndrome, Beckwith--Wiedemann syndrome, multiple endocrine neoplasia type 1, familial adenomatous polyposis, neurofibromatosis 1, and LS), the incidence of ACC, although much higher than the general population, is still low to warrant serial imaging. Steroid profiling ([Fig. 2](#fig2){ref-type="fig"}) is an attractive alternative that could help diagnose ACC much earlier in the natural history of the disease \[[@B15]\]. In our patient, steroid profiling confirmed our suspicion of ACC after discovery of adrenal mass \[[@B16]\]. Whereas in this case, steroid profiling did not change our management, after appropriate validation, this test could be offered as a case-detection, noninvasive, and radiation-free test to patients at high risk for ACC. Surgical resection is the mainstay of treatment of ACC with a goal to achieve a microscopic tumor clearance (R0) resection. Further management depends on the stage of ACC and prognostic markers derived from pathology examination.

![Urine steroid profiling. HRAM, high resolution, accurate mass.](js.2019-00050f2){#fig2}

3. Conclusion {#s10}
=============

In summary, we present a patient with LS whose only manifestation was ACC, adding to the available literature of only 12 cases. We also demonstrated that steroid profiling could serve as a noninvasive diagnostic and potentially as a case-detection tool for patients at risk for ACC.
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